
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
Nicholas Vogelzang, MD, FASCO, FACP, comments on managing an elderly patient with hormone-sensitive prostate cancer with apalutamide and ADT based on data demonstrated by the phase 3 TITAN trial.
Case: A 76-Year-Old Male With Recurrent Castrate-Sensitive Prostate Cancer
History
Currently
Clinical workup
Treatment and Follow-Up
